Cytiva and Pall Life Sciences complete integration to create a global innovation and solutions leader in biotechnology

Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, says: "The biotechnology industry is at the start of a new era. New modalities are emerging, there is greater emphasis on local manufacturing, and we are accelerating the adoption of digital solutions. Our customers need a partner that can meet them at every part of their process. Uniting Cytiva and the life sciences business of Pall gives us the focus, expertise, and talent to help our customers discover, develop, and deliver the next generation of novel therapeutics."
Comunicato Precedente

next
Comunicato Successivo

next

Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, says: "The biotechnology industry is at the start of a new era. New modalities are emerging, there is greater emphasis on local manufacturing, and we are accelerating the adoption of digital solutions. Our customers need a partner that can meet them at every part of their process. Uniting Cytiva and the life sciences business of Pall gives us the focus, expertise, and talent to help our customers discover, develop, and deliver the next generation of novel therapeutics."

Cytiva's now expanded and differentiated portfolio will better enable customers to accelerate therapeutics from discovery to delivery. The portfolio now includes industry-leading product brands including Allegro, Supor, iCELLis, Kleenpak, and Pegasus, in addition to ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex, and Xuri*.

Meet Cytiva's leadership team here.

For additional video assets, please contact Cytiva.

*Allegro, Supor, iCELLis, Kleenpak, Pegasus, ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex, and Xuri are trademarks of Global Life Solutions USA LLC or an affiliate doing business as Cytiva.

About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 16 000 associates in more than 40 countries, we're driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com

Video - https://mma.prnewswire.com/media/2066429/Cytiva_President_and_CEO_Emmanuel_Ligner.mp4 

Cision View original content:https://www.prnewswire.co.uk/news-releases/cytiva-and-pall-life-sciences-complete-integration-to-create-a-global-innovation-and-solutions-leader-in-biotechnology-301812184.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;